Probing the Impact of Gender-Affirming Hormone Treatment on Odor Perception

2019 ◽  
Vol 45 (1) ◽  
pp. 37-44 ◽  
Author(s):  
Georg S Kranz ◽  
Ulrike Kaufmann ◽  
Rupert Lanzenberger

Abstract Evidence suggests that women outperform men in core aspects of odor perception, and sex hormones may play a significant role in moderating this effect. The gender-affirming treatment (GAT) of transgender persons constitutes a powerful natural experiment to study the psychological and behavioral effects of high dosages of cross-sex hormone applications. Therefore, our aim was to investigate the effects of GAT on odor perception in a sample of 131 participants including female and male controls, as well as transmen and transwomen over their first 4 months of gender transition. The Sniffin’ Sticks test battery was used to measure odor detection, discrimination, and identification at baseline, as well as 1 and 4 months after the start of GAT. Plasma levels of estradiol, testosterone, and sex hormone-binding globulin were analyzed for each assessment point. Results revealed no significant change of olfactory performance in the two transgender groups compared with female and male controls. There was no significant difference between groups at baseline or any other time point. Neither biological sex, nor gender identity had an influence on odor perception. Moreover, there was no significant correlation between sex hormones and odor perception and between GAT-induced changes in sex hormones and changes in odor perception. Our results indicate that the effects of sex hormones on olfactory performance are subtle, if present at all. However, our results do not preclude hormonal effects on odors not included in the Sniffin’ Sticks test battery, such as body odors or odors associated with sex.

1984 ◽  
Vol 2 (6) ◽  
pp. 652-654 ◽  
Author(s):  
S R Plymate ◽  
F H Stutz ◽  
B L Fariss

It has been suggested that the level of sex hormone binding globulin (SHBG) is a better predictor of response of breast cancer to hormone treatment than the measurement of estrogen receptor (ER). However, no correlation of SHBG with ER status has been shown. To define the relationship between SHBG and the ER, the following study was undertaken. Fifty women with breast cancer and known ER status had SHBG measured by dextran-coated charcoal saturation analysis. The mean SHBG in all ER-positive patients was 20.7 +/- 2.4 (ng DHT bound/mL) and in all ER-negative patients was 11.5 +/- 2.0 (p less than 0.01). The mean premenopausal level of SHBG was 22.2 +/- 3.8 ng/mL and postmenopausal level was 20.0 +/- 5.7 ng/mL. There was no significant difference between these groups. ER-positive patients on tamoxifen had a SHBG of 29.8 +/- 9 ng/mL and ER-negative subjects on tamoxifen had a mean SHBG level of 8.3 +/- 3.4 ng/mL, p less than 0.01. ER-positive patients have a higher SHBG level than ER-negative patients; furthermore, this difference between ER-positive and ER-negative subjects was further demarcated by changes in SHBG after the subjects had been placed on tamoxifen.


2011 ◽  
pp. P1-338-P1-338
Author(s):  
Chiara Cattabiani ◽  
Gianpaolo Ceda ◽  
Fulvio Lauretani ◽  
Stefania Bandinelli ◽  
Giulia Schiavi ◽  
...  

2014 ◽  
Vol 23 (12) ◽  
pp. 2943-2953 ◽  
Author(s):  
Kelly A. Hirko ◽  
Donna Spiegelman ◽  
Walter C. Willett ◽  
Susan E. Hankinson ◽  
A. Heather Eliassen

Author(s):  
Isabel Pimentel ◽  
Bingshu E Chen ◽  
Ana Elisa Lohmann ◽  
Marguerite Ennis ◽  
Jennifer Ligibel ◽  
...  

Abstract Background Metformin has been associated with lower breast cancer (BC) risk and improved outcomes in observational studies. Multiple biologic mechanisms have been proposed, including a recent report of altered sex hormones. We evaluated the effect of metformin on sex hormones in MA.32, a phase III trial of nondiabetic BC subjects who were randomly assigned to metformin or placebo. Methods We studied the subgroup of postmenopausal hormone receptor-negative BC subjects not receiving endocrine treatment who provided fasting blood at baseline and at 6 months after being randomly assigned. Sex hormone-binding globulin, bioavailable testosterone, and estradiol levels were assayed using electrochemiluminescence immunoassay. Change from baseline to 6 months between study arms was compared using Wilcoxon sum rank tests and regression models. Results 312 women were eligible (141 metformin vs 171 placebo); the majority of subjects in each arm had T1/2, N0, HER2-negative BC and had received (neo)adjuvant chemotherapy. Mean age was 58.1 (SD=6.9) vs 57.5 (SD=7.9) years, mean body mass index (BMI) was 27.3 (SD=5.5) vs 28.9 (SD=6.4) kg/m2 for metformin vs placebo, respectively. Median estradiol decreased between baseline and 6 months on metformin vs placebo (−5.7 vs 0 pmol/L; P < .001) in univariable analysis and after controlling for baseline BMI and BMI change (P < .001). There was no change in sex hormone-binding globulin or bioavailable testosterone. Conclusion Metformin lowered estradiol levels, independent of BMI. This observation suggests a new metformin effect that has potential relevance to estrogen sensitive cancers.


Sign in / Sign up

Export Citation Format

Share Document